The broader market is finally supportive of the sector and barring a reversal we should start to see a nice run up into JPM next week. At the very least.
Holy crap, BMY is buying CELG. This is one hell of a way to start the XLRN is aNew Year and JPM week. It is unfortunate for the sector that.
It is brutal out there for bears and bulls alike. While the trend seems to be lower the market continues to have little rips higher. I still lean towards another.
Not a ton of news as the year closes down. It seems like the market wants to whiplash investors as we bounce around with no clear trends. It does not.
BriaCell presented some data from the ongoing Phase IIa combination clinical trial of Bria-IMT™ with Merck’s (NYSE: MRK) KEYTRUDA® [(pembrolizumab)], as listed in ClinicalTrials.gov as NCT03328026, in advanced breast cancer.
The market did a lot better to start the week than I would have thought and that strength continues today. At this point, I think everyone does not really trust.
The market can always surprise and I was surprised yesterday with the sector strength. The broader market did better than I expected but the sector clearly outperformed. It is only.
China is back in the news and for good or ill, the sector fundamentals do not matter. Right now it is all about China and the broader market will pull.
It is certainly a great start to the week with generally good news from ASH, merger Monday, and easing trade tensions. If we do not get a gap and run.
Yesterday as a bad day for the sector as it was red with a positive broader market backdrop. To be fair it was a rather odd day in the sector.
I guess we did not get the turn around that could have been a positive sign. There is still a chance for a turnaround Tuesday as we gap lower at.
In a previous interview, BriaCell (TSX:BCT.V) (OTCQB:BCTXF) (or the Company)’s President and CEO, Dr. Bill Williams cited as a near-term catalyst data from the Company’s ongoing Phase IIa combination clinical.